High stability hybrids producing monoclonal antibodies against human C-reactive protein.
This report shows how high stability hybrids producing monoclonal antibodies against human C-reactive protein were raised and selected. Monoclonal antibodies can be produced in large enough quantities through this method, to allow for the design and use of quantitative C-reactive protein determination on a clinical scale. This novel strategy consisted of the following: growing the hybrids and freezing them before cloning in order to assure stability and selecting the hybrids from those producing high titres in mouse ascite induction. Two monoclonal antibodies of high stability and great potential for large scale production have been developed in this manner. Production on a large scale of these monoclonal antibodies against human C-reactive protein can be useful both in clinical quantification and in physiological studies concerning its still unknown in vivo function.